All News
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.
In this process, scientists used ultrasonic waves—the same low-frequency waves used in medical sonograms—to activate a specific group of genetically marked cells.
Statistically significant weight loss and liver fat reduction were seen across all dosage groups—with no changes to diet or exercise.
It’s not likely that the FDA will give the cancer drug sintilimab immediate attention, since the research was conducted exclusively in China.
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
The vaccine delivered more than $12 billion in revenue to Pfizer and the company expects those earnings to vastly increase this year to $32 billion.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
WuXi Biologics was amongst those on the list, with the U.S. stating that it was unable to verify the legitimacy and reliability of the company in its use of U.S. exports.
The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.
After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer’s patients.
Much of Amgen’s modest gains in the year can be attributed to its manufacturing partnership with Eli Lilly and an increase in sales for EVENITY.
The U.S. Food and Drug Administration announced they are investigating a possible death risk for TG Therapeutics’ Ukoniq (umbralisib).
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.